Imagion Biosystems receives AU$2.5 million in R&D tax incentives
ASX Announcement: MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to report
ASX Announcement: MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to report
We recently announced that our MagSense® diagnostic technology has the potential to target prostate cancer tumors, making this the second cancer type the technology has
Our Chairman and CEO Bob Proulx was a recent guest at the Fear and Greed podcast, discussing our pursuit of better, more precise imaging solutions to
Imagion Bio CEO, Robert Proulx, presents company information to investors at the 2022 Switzer Small & Micro Cap Conference in September. Video Transcript: Thank you,
https://youtu.be/iH0a08glQYo Imagion to present prostate cancer research data at World Molecular Imaging Congress MagSense® molecular imaging agent shows high specificity and selectivity MELBOURNE — Imagion
Today, we released our Appendix 4D and Half-Year Financial Report for the half-year ending 30 June 2022 to the ASX. 1H2022 Highlights: MagSense® HER2 breast
Imagion has released the Quarterly Activity Report and Appendix 4C for the period ending on 30 June 2022. The announcement highlights: MagSense® HER2 imaging agent
Lipids are frequently used to form drug carrying nanoparticles because of their favorable biocompatibility. However, construction of such drug-carrying lipid nanoparticles often involves multiple steps.
Imagion Biosystems recording of the Q&A session at the 2022 Annual General Meeting. Imagion Biosystems’ board of directors answer questions from shareholders at the AGM
In accordance with ASX Listing Rule 3.13.2 and section 251AA of the Corporations Act 2001, Imagion Biosystems Limited advises the results of its Annual General
Stay informed about our latest news and developments.
© Imagion Biosystems, Ltd. All Rights Reserved | Privacy Policy | Terms & Conditions | Careers | Corporate Governance